Navigation Links
Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
Date:1/22/2013

SEATTLE, Jan. 22, 2013 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) is pleased to announce the January publication of a paper titled "Enzymatic Discovery of a HER-2/neu Epitope That Generates Cross-Reactive T-cells", authored by Henle et al, J.Immunol. (2013), 190, 479-488.  This work, performed in the laboratory of Dr Keith Knutson at Mayo Clinic, describes the discovery of a novel HER-2/neu Class I epitope (p373-382) TapImmune has licensed from Mayo Clinic for the development of breast cancer vaccines.  The significance of this work is that this newly discovered antigen is a naturally occurring antigen processed by the proteasome and elicits peptide-specific T-cell responses.  This results in stronger binding to HLA-A2 and more efficient killing of HER-2/neu positive breast cancer cells by activated T-cells compared to the Class I epitope, p369-377 (E75) which was not naturally processed by the proteasome.

"These results provide an explanation of the molecular immunology behind our approach to HER-2/neu immunotherapy," said Mark Reddish Vice President of TapImmune Inc.  "These data describe how the HER-2/neu protein is processed by the proteasome to then be presented for immune recognition and killing.  By revealing the true identity of the immunodominant epitope responsible for class I mediated killing of HER-2/neu positive tumors, it is now possible to generate a true second generation vaccine that incorporates the correct target as it naturally appears on human tumors.  For nearly 20 years the immunology of this key protein has been clouded by contradictory observations, and these data finally provide an understanding of the 'natural target' displayed on human tumors. We expect to combine this immunodominant peptide with our broadly reactive helper peptides that are currently being tested in a phase I trial, to create a tru
'/>"/>

SOURCE TapImmune Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Report Details NCPA Efforts to Drive Greater Medication Adherence
2. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
3. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
4. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
5. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
6. Physician Details Problems with Medicare Approval Process for Power Wheelchairs
7. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
8. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
9. MAQUET Cardiovascular Announces U.S. Food and Drug Administration Panel Votes To Reclassify Intra-Aortic Balloon Pumps To A Class II Designation In Certain Indications
10. Barrack, Rodos & Bacine Files Class Action Lawsuit Against St. Jude Medical, Inc.
11. Thomson Reuters Empowers Drug Development and Clinical Professionals to Develop Better, Faster Clinical Trials with Best-in-Class Intelligence Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... 30, 2015 Eisai Inc. announced today that ... United States , European Union and ... respectively) for eribulin, for the treatment of patients with ... chemotherapy for advanced or metastatic disease. ... pivotal global Phase 3 clinical trial (Study 309), which ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... July 27, 2011 Reportlinker.com announces that ... in its catalogue: India ... Till 2016 http://www.reportlinker.com/p0575381/India-Cardiac-Catheters-and-Guidewires---Market-Trends-Till-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... This market report provides vital ...
... 26, 2011 Symmetry Medical Inc. (NYSE: SMA ... orthopaedic device industry and other medical markets, announced today that ... period ending July 2, 2011 before the market opens on ... conference call at 8:00 a.m. ET on Thursday, August 4, ...
Cached Medicine Technology:India Cardiac Catheters and Guidewires - Market Trends Till 2016 2India Cardiac Catheters and Guidewires - Market Trends Till 2016 3Symmetry Medical to Report Second Quarter 2011 Financial Results on August 4, 2011 2
(Date:7/30/2015)... ... July 30, 2015 , ... OSF Healthcare System has ... 2015 Most Wired Survey conducted by Hospitals & Health Networks. This marks the fourth ... operated by The Sisters of the Third Order of St. Francis . , ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... The connection between a healthy head of ... The loss of a full head of hair can have a devastating impact on ... person is perceived in the work place, the consequences of hair loss are not to ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, the refreshing ... as a simple way to get the natural ingredients that may help with ...
(Date:7/30/2015)... Marathon, FL (PRWEB) , ... July 30, 2015 ... ... streaming software, TikiLIVE, has worked to protect victims in San Diego, California’s Gaslamp ... cameras used by Gaslamp Quarter Plaza actively monitor the area for any ...
(Date:7/30/2015)... ... 2015 , ... The American Telemedicine Association (ATA) is seeking ... exclusively on telemedicine, telehealth and mHealth. The meeting, expected to attract over 6,000 ... May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting attracts the world’s ...
Breaking Medicine News(10 mins):Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3
... by preventing disease have been around for centuries. Now, ... how they will be combined with existing treatments is ... Michigan Health System recommend that a national strategy be ... so that cancers with less effective treatment options are ...
... has long been known that getting enough vitamin D is key ... issue, experts say. According to the Endocrine Society, very few ... is one of the best sources of the nutrient. People ... phosphorus and bone metabolism abnormalities, which can lead to a number ...
... that there can be a significantly higher risk of ... shingles, or herpes zoster, attack. The findings, which support ... published in The Journal of Infectious Diseases ... MS is an autoimmune disease that affects the brain ...
... in the current issue of Technology & Innovation, ... reports on the bright future and enormous need for ... suffering from debilitating and deadly diseases. ... therapy through "simple cell replacement" procedures to restructure damaged ...
... , When a person has a family history of cancer, ... refusing to have preventive tests. Advice from genetic counselling units ... Now, a scientific team has validated the ,Escala de Preocupacin ... Scale), the first of its kind in the Spanish language, ...
... Black and other minority children in the United States spend ... listening to music, using computers and playing video games, new ... previous media use studies done by the Kaiser Family Foundation ... consume an average of 13 hours of media content a ...
Cached Medicine News:Health News:U-M researchers advocate national strategic approach to therapeutic cancer vaccines 2Health News:New Guidelines Put Focus on Vitamin D Deficiency 2Health News:Study finds shingles may be related to elevated risk of multiple sclerosis 2Health News:The future of stem cell applications challenging, bright 2Health News:Scale helps to measure the utility of genetic counseling in tackling fear of cancer 2Health News:Greater Media Use Found Among Minority Kids 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: